Anixa Biosciences Inc., a biotechnology company dedicated to cancer treatment and prevention, has announced a forthcoming presentation on its Phase 1 clinical trial for an ovarian cancer CAR-T immunotherapy. Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and the trial's principal investigator, will present the e-poster at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025. The event is scheduled to take place from June 19-21, 2025, in Vienna, Austria. The trial involves autologous T-cells genetically engineered with a chimeric receptor aimed at targeting the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The presentation will provide insights into the preliminary findings of this ongoing study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.